Kimberly Gentile - Nov 25, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
SVP, Clinical Operations
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Nov 25, 2021
Transactions value $
-$200,826
Form type
4
Date filed
11/26/2021, 03:30 PM
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +3.75K +48.76% $0.00 11.4K Nov 25, 2021 Direct
transaction BHVN Common Shares Tax liability -$201K -1.74K -15.19% $115.55* 9.7K Nov 25, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 -3.75K -50% $0.00 3.75K Nov 25, 2021 Common Shares 3.75K Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 Each restricted share unit represents the contingent right to receive one common share of the issuer.
F3 The reporting person was granted 15,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F4 Not applicable.